Lilly Treatment Slows Alzheimer’s Course in Some PatientsShannon Pettypiece and Michelle Fay Cortez
Eli Lilly & Co. said its experimental Alzheimer’s treatment slowed the decline of cognition in some patients while failing to meet the primary goals of two large trials. The shares rose.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.